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Resumo 
O cancro da mama é a principal causa de morte por cancro em mulheres em todo o 
mundo, sendo os tumores recetor de estrogénio positivo [ER+] os de maior prevalência. Os 
estrogénios são responsáveis pelo desenvolvimento destes tumores. Deste modo, várias 
estratégias terapêuticas foram desenvolvidas para bloquear a ação estrogénica, tais como o 
uso dos modeladores seletivos dos recetores de estrogénio (SERMs), os inativadores 
seletivos dos recetores de estrogénio (SERDs) e os inibidores da aromatase (AIs). Os IAs 
têm provado ser uma das melhores opções para o tratamento e prevenção destes tumores 
em mulheres na pós-menopausa, pela sua capacidade de bloquear a enzima aromatase, 
fundamental na biossíntese de estrogénios. Embora muito eficazes, os AIs utilizados na 
clínica induzem  alguns efeitos colaterais graves, incluindo a perda de massa óssea e o 
desenvolvimento de resistência à terapia. Deste modo, é importante o desenvolvimento de 
novos compostos potentes, com menos efeitos secundários. 
Este trabalho focou-se no estudo de novos compostos como potenciais AIs, 
sintetizados a partir de modificações estruturais na molécula da androstenediona, um dos 
substratos da aromatase. Para isso foi avaliada a atividade anti-aromatásica, os efeitos 
biológicos e os mecanismos anti-tumorais de quatro novos compostos (57, 58, 59 e 60). 
Os estudos in vitro foram realizados numa linha celular não-tumoral de fibroblastos 
(HFF-1), numa linha celular humana de cancro da mama recetor de estrogénio positivo 
com sobre-expressão da aromatase (MCF-7aro) e numa linha celular humana de cancro da 
mama recetor de estrogénio negativo (SK-BR-3). 
Os resultados demonstraram que todos os novos esteróides são potentes IAs sendo 
capazes de reduzir a viabilidade das células de cancro da mama hormono-dependente, 
sem afetar as células não tumorais. Os novos IAs induziram ainda paragem do ciclo celular 
e morte celular por apoptose pela via mitocondrial. 
Em conclusão, os efeitos anti-proliferativos dos novos esteróides são devidos a uma 
paragem na progressão do ciclo celular e a mecanismos de morte celular. Este trabalho 
poderá contribuir para o desenho e síntese de compostos mais eficazes e para a 
compreensão dos mecanismos de supressão tumoral associados ao tratamento com IAs.  
Palavras-chave: inibidores da aromatase, cancro da mama estrogénio-
dependente, terapia endócrina. 
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Abstract 
Breast cancer is the most common cause of cancer death in women worldwide, 
being the most prevalent the estrogen receptor-positive [ER+] breast tumors. Estrogens 
are responsible for the development of ER+ breast tumors. Thus, several therapies have 
been developed to block estrogen actions, such as the selective estrogen receptor 
modulators (SERMs), the selective estrogen receptor downregulators (SERDs) and the 
aromatase inhibitors (AIs). The AIs have proved to be one of the best options for the 
treatment and prevention of these tumors in postmenopausal women, since the enzyme 
aromatase is fundamental for estrogens biosynthesis. Though the AIs used in clinic are 
effective, they induce serious side effects including bone loss and the development of 
therapy resistance. For this, the search for novel potent compounds, with fewer side 
effects, is currently needed. 
The present work focused on the study of new steroidal compounds as potential 
AIs, synthesized from structural modifications on androstenedione molecule, an 
aromatase substrate. The anti-aromatase activity, the biological effects and the underlying 
anti-tumor mechanisms of four new compounds (57, 58, 59 and 60) were evaluated. The 
in vitro studies were performed in a non-tumor fibroblastic cell line (HFF-1), an estrogen 
receptor-positive (ER+) human breast cancer cell line that overexpresses aromatase (MCF-
7aro) and an estrogen receptor-negative (ER-) human breast cancer cell line (SK-BR-3).  
The results revealed that all the steroids are potent AIs, capable of decreasing the 
viability of the hormone-dependent breast cancer cells without affecting the non-tumor 
fibroblastic cells. In addition, these new AIs induced  cell cycle arrest and cell death by 
apoptosis via the mitochondrial pathway.  
In conclusion, the anti-proliferative effects of these new steroids are mainly due to 
cell cycle arrest and cell death mechanisms. This work might contribute to the design and 
synthesis of more effective compounds and to the elucidation of the tumor suppressor 
mechanisms associated with AIs treatment.  
Keywords: aromatase inhibitors, estrogen-dependent breast cancer, endocrine 
therapy. 
 
 
 
  
ix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
x 
Table of contents 
 
Author´s Publications ....................................................................................................... ii 
Aknowledgments/Agradecimentos ................................................................................. iii 
Resumo ............................................................................................................................ vi 
Abstract ....................................................................................................................... viiiiii 
Table of contents ............................................................................................................... x 
Index of figures ............................................................................................................... xii 
Index of tables ................................................................................................................. xii 
Abbreviations List .......................................................................................................... xiv 
CHAPTER I – Introduction…………………………………………………………………………………….1 
1. Hormone-dependent Breast Cancer ...................................................................... 3 
1.1 Breast cancer:incidence and risk factors .............................................................. 3 
2. Estrogens ............................................................................................................... 4 
2.1 Estrogen Biosynthesis .......................................................................................... 5 
2.2 Aromatase.………………………………...…………………………………………………………….6 
2.3 Estrogen Receptors (ER) ..................................................................................... 8 
2.4 Pathways of Estrogen Signaling ......................................................................... 11 
3. Hormonal therapy in breast cancer treatment ..................................................... 13 
3.1 Seletive ER modulators (SERMs) and seletive ER downregulators (SERDs) .... 13 
3.2 Aromatase Inhibitors (AIs) ................................................................................ 15 
3.2.1 Non-steroidal AIs ................................................................................................ 17 
3.2.2. Steroidal AIs .......................................................................................................19 
AIM of study ................................................................................................................... 23 
CHAPTER II - Materials and methods ........................................................................... 25 
1. Materials .............................................................................................................. 27 
2. Compounds .......................................................................................................... 27 
3. Preparation of the AIs, Testosterone and Estradiol ............................................ 28 
4. Cell Cultures ......................................................................................................... 28 
5. Preparation of charcoal heat-inactivated fetal bovine serum (CFBS) ................. 29 
6. Preparation of charcoal pellets ............................................................................ 29 
7. In cell aromatase assay ........................................................................................ 29 
8. Cell viability assay ................................................................................................ 30 
9. Western Blot analysis ........................................................................................... 31 
10. Morphological Studies ......................................................................................... 32 
  
xi 
11. Cell cycle analysis ................................................................................................... 32 
12. Cell death analysis  .............................................................................................. 33 
12.1 Caspase activity ................................................................................................ 33 
12.2 Intracellularr reactive oxygen species (ROS) .................................................. 34 
13. Statistical analysis ................................................................................................ 34 
CHAPTER III - Results ................................................................................................... 35 
1. Evaluation of aromatase inhibition ..................................................................... 37 
2. Cell viability assay in HFF-1 cell line ................................................................... 38 
3. Effects on MCF-7aro cell viability ........................................................................ 39 
4. Caracterization of the mechanism of AIs action: dependence on aromatase and 
androgen-receptor .......................................................................................................41 
5. Western blot analysis ........................................................................................... 44 
6. Cell viability in E2-treated MCF-7aro cells versus SK-BR-3 cells ....................... 45 
7. Morphological studies ......................................................................................... 47 
8. Cell cycle analysis................................................................................................. 49 
9. Cell death analysis ............................................................................................... 50 
CHAPTER IV - Discussion .............................................................................................. 53 
CHAPTER V - Bibliography ............................................................................................ 57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
xii 
Index of figures  
 
Figure  1: Worldwide incidence of breast cancer. The incidence of new diagnoses per 
100,000 women per year. ................................................................................................. 3 
Figure 2: Biosynthesis of estrogens .................................................................................. 5 
Figure 3: Aromatase Gene – CYP19 .................................................................................. 6 
Figure 4: Tertiary structure of aromatase isolated from human placenta ....................... 7 
Figure 5: The active site of aromatase .............................................................................. 8 
Figure 6: Distribution of ERα and ERβ by the different organs ...................................... 9 
Figure 7: Schematic representation of the human ERα and ERβ structures ................. 10 
Figure 8: Schematic representation of ER signaling pathways .......................................12 
Figure 9: Selective ER modulators (SERMs) ...................................................................14 
Figure 10: Chemical structure of the non-steroidal AIs aminoglutethimide, fadrozol, 
anastrozole and letrozole .................................................................................................19 
Figure 11: Chemical structure of the steroidal AIs testolactone, formestane and 
exemestane ......................................................................................................................21 
Figure  12: Aromatase activity in MCF-7aro cells ........................................................... 37 
Figure 13: Effects of steroidal compounds on HFF-1 cell viability analysed by MTT .... 38 
Figure 14: Effects of steroidal compounds on MCF-7aro cell viability analysed by MTT39 
Figure 15: Effects of steroidal compounds on MCF-7aro cell membrane integrity analysed 
by LDH assays ................................................................................................................. 40 
Figure 16: Effects of steroidal compounds on viability of E2-treated MCF-7aro cells, 
analysed by MTT ..............................................................................................................41 
Figure 17: Comparison of the effects of compounds 57, 58, 59 and 60 (1 -25 µM) in 
viability of MCF-7aro cells stimulated with testosterone (T) or estradiol (E2), during 6 days
 ........................................................................................................................................ 42 
Figure 18: Effects of steroidal compounds on CDX-treated MCF-7aro cells viability 
analysed by MTT ............................................................................................................. 43 
Figure 19: Comparison of the effects of different concentrations of compounds 57, 58, 59 
and 60 (1 -25 µM) in viability of MCF-7aro cells stimulated with testosterone (T) and with 
or whit out Casodex (CDX), during 6 days ..................................................................... 44 
Figure 20: Western Blot analysis of Aromatase ............................................................. 45 
Figure 21: Effects of steroidal compounds on SK-BR-3 cell viability analysed by MTT 46 
Figure 22: Comparison of the effects of compounds 57, 58, 59 and 60 (1 - 25 µM) in 
viability of MCF-7aro cells stimulated with Estradiol (E2) and in SK-BR-3 cells, during 6 
days ................................................................................................................................. 47 
Figure 23: Effects of compounds (10 µM) on MCF-7aro cells morphology after 6 days of 
treatment cells ................................................................................................................ 48 
  
xiii 
Figure 24: Effects of compounds on MCF-7aro cell cycle progression .......................... 49 
Figure 25: Activation of caspase-7 and -9 in MCF-7aro cells treated with AIs (10 μM) after 
3 days of incubation ........................................................................................................ 50 
Figure 26: Formation of ROS in MCF-7aro cells treated with compounds after 3 days . 51 
 
Index of tables 
Table 1 - Effects of the different treatments on cell cycle in MCF-7aro cells for 3 days of 
incubation………………………………………………………………………………………………………….4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
xiv 
Abbreviations List 
 
AF-1 activation function 1  
AF-2 activation function 2  
AG aminoglutethimide  
AI(s) aromatase inhibitor(s)  
AKT protein kinase B  
AP-1 activator protein 1 (transcription 
factor)  
Bcl-2 B cell lymphoma 2  
BCS breast cancer survivors 
BRAC1 breast cancer 1, early onset 
(gene)  
BRAC2 breast cancer 2, early onset 
(gene)  
cAMP cyclic adenosine monophosphate 
CCCP carbonyl cyanide m-
chlorophenylhydrazone 
CDX Casodex  
CFBS charcoal-treated bovine serum  
CoA co-activator  
CYP cytochrome P450  
CYP19 aromatase  
DBD DNA-binding domain  
DCF 2’,7’-dichlorofluorescein 
DCFH2 2’,7’-dichlorodihydrofluorescein 
DCFH2-DA 2’,7’-
dichlorodihydrofluorescein diacetate  
DMEM Dulbecco’s Modified Eagle 
Medium  
DMSO dimethylsulfoxide  
DR Dimerization Domain 
E1 estrone  
E2 17β-estradiol or estradiol  
E3 estriol  
EDTA ethylenediaminetetraacetic acid  
EGF epidermal growth factor  
EGFR epidermal growth factor receptor  
ER(s) estrogen receptor(s)  
ER+ estrogen receptor positive 
(hormone-dependent or estrogen-
dependent)  
ER- estrogen receptor negative  
ERE(s) estrogen response element(s)  
Exe Exemestane  
FBS fetal bovine serum  
FDA U.S Food and Drug Administration  
FSH follicle-stimulating hormone  
GF growth factor 
GFR(s) growth factor receptor(s)  
GPCR(s) G protein-coupled receptor(s) 
GPR30 G protein-coupled estrogen 
receptor 30  
HER2 human epidermal growth factor 
receptor 2  
HFF-1 human foreskin fibroblasts-1 cell 
line  
HIF inducible hypoxia factors 
IGF1 insulin-like growth factor 1  
IGFR1 insulin-like growth factor 1 
receptor  
LBD Ligand-binding Domain 
LDH lactate dehydrogenase  
MAPK mitogen-activated protein kinase  
MCF-7aro estrogen receptor-positive 
breast cancer cell line overexpressing 
aromatase  
MEM Minimum essential medium  
MFI mean fluorescence intensity
  
ii 
MISS membrane-initiated steroid 
signaling  
mTOR mammalian target of rapamycin  
MTT tetrazolium salt 3-(4,5-
dimethylthiazol-2-yl)-2,5- 
difenyltetrazolium  
NADPH nicotinamide adenine 
dinucleotide phosphate  
NISS nuclear-initiated steroid signaling  
NLS nuclear localization signaling  
PGE2 prostaglandin E2  
p53 tumor protein 53 (gene)  
PI propidium iodide  
PI3K phosphatidylinositide 3-kinase  
PMA phorbol 12-myristate 13-acetate  
PR progesterone receptor  
PTEN tumor suppressor phosphatase 
and tensin homolog  
ROS reactive oxygen species  
SERD(s) selective estrogen receptor 
downregulator(s)  
SERM(s) selective estrogen receptor 
modulator(s)  
SK-BR-3 estrogen receptor negative 
breast cancer cell line  
SP-1 specificity protein-1 
Src tyrosine protein kinase  
STA staurosporine  
T testosterone  
TF(s) transcription factor(s)  
TNF-α tumor necrosis factor alpha  
3β-HSD 3β-hydroxysteroid 
dehydrogenase  
4-OHA 4-hydroxyandrostenedione or 
formestane  
17β-HSD 17β-hydroxysteroid 
dehydrogenase  
ΔΨm mitochondrial transmembrane 
potential 
 
 
 
 
 
 
  
1 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter I 
Introduction 
 
 
 
 
 
 
 
 
 
  
  
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3 
1. Hormone-dependent Breast Cancer  
1.1. Breast cancer: incidence and risk factors 
Breast cancer is the main cause of death in women worldwide (figure 1). Although 
it  can also occur in men, it is 100 times more common in women (1). There is a wide 
geographic variation in incidence of breast cancer, and in 2012 the highest occurred in 
Europe. In Portugal, approximately 86% of new cases were diagnosed in that year, of 
which 18% women’s die victims of that disease (2). The majority of breast cancers are 
hormone-dependent and express the estrogen-receptor. Arround 65% of these tumors 
occur in premenopausal women and 75% in postmenopausal women (3). However, taking 
into account the advances  in recent years to improve the screening and treatment of this 
disease, it has become possible to treat women with breast cancer at early stages, thus 
promoting the survival rate of women free of disease.  
 
Figure 1: Worldwide incidence of breast cancer. The incidence of new diagnoses per 100,000 women 
per year. Adapted from (4) 
Breast cancer is a heterogeneous group of diseases. According to the World Health 
Organization (WHO), breast cancer is subdivided into 21 different histological types based 
on cell morphology, growth and architecture standards (5). The majority of breast cancers 
develop from the epithelial cells lining the ducts or the lobules, being classified as ductal 
or lobular carcinomas (1). In the last decade, the research focused on the understanding of 
the heterogeneity of breast cancer and of the prediction of tumor behavior to improve 
therapeutic strategies. Using molecular parameters breast cancers were divided into 
Luminal A, which includes the estrogen or progesterone receptor (ER/PR) positive and 
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receptor negative human growth factor 2 negative (HER2-) while the ER+/PR+ and HER2+ 
belong to Luminal B. The triple negative breast cancer (ER-/EP-/HER2-) belongs to the 
basal like subtype (1). 
There are a number of known risk factors for the development of breast cancers. 
One of the most important is the occurrence of mutations in genes like: BRCA1, BRCA2, 
CHEK2, p53 and ATM (6),(7). Other important risk factors are the age, early menses, late 
menopause, null parity, lactation failure, hormone replacement therapy, oral 
contraception and treatment with the synthetic estrogen diethylstilbestrol. The obesity is 
also considered a risk factor. The reasons why women with higher body fat content are 
more likely to develop breast cancer are not yet clear, but it may be related to the higher 
expression of aromatase in adipocytes (4).  
The treatment of breast tumors has advanced significantly in recent decades, 
improving the quality of life of women diagnosed with this cancer. Endocrine therapy is 
the standard cancer treatment for hormone-dependent breast cancer in post-menopausal 
women. The estrogen is responsible for the development of ER+ tumors, thus by 
decreasing the amount of estrogens produced or by inhibiting their action it may be 
reduced the risk of developing such tumors. Among them, we highlight the selective 
estrogen receptor modulators (SERMs), selective estrogen receptor down-regulators 
(SERDs) and the aromatase inhibitors (AIs). However, for the triple negative breast 
cancer, the treatment options are more limited and there is still no specific treatment (8). 
 
2. Estrogens  
Estrogens are steroidal sex hormones that are synthesized from cholesterol and 
primarily secreted by the ovaries. These steroids circulate in the bloodstream bound to 
proteins, being the breast, uterus, ovaries, brain, heart and liver their major target tissues 
(9). Estrogens are divided into three types: estrone (E1), 17-β- estradiol (E2) and estriol 
(E3), being E2 the most potent (4, 9). Estrogens, in particular E2, participate in the 
regulation of the growth, differentiation and homeostasis of serial tissues (10). However, 
one of the most important effects of estrogens is associated with stimulation of breast 
tissue growth (11). Several studies, established a relationship between the development of 
breast cancer and estrogens (12). One explanation for this correlation was based on the 
fact that there is increased cellular proliferation (13), which can induce an increased risk of 
DNA lesions. This damage can result from the production of oxidative metabolites, DNA 
breaks and accumulation of genomic mutations (11). However, estrogens may have 
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beneficial effects as protective against cardiovascular disease, by regulating cholesterol 
level, maintaining bone density and preventing osteoporosis (14, 15). The effects of 
estrogen in target tissues can be mediated by the estrogen receptors (ER), ERα or ERβ 
(16).  
 
2.1. Estrogen Biosynthesis 
In premenopausal women the ovary is the principal source of estrogen, however 
during pregnancy it is also synthesized in the placenta (17). After menopause, the estradiol 
is synthesized in peripheral tissues, especially in adipose tissue, and from circulating 
steroid precursors from adrenal cortex (15).  
The synthesis of estrogens are catalyzed by the action of selective and complex 
enzymes that belong to the cytochrome P450 enzyme family (CYP450) (18). The synthesis 
of estrogens starts with the production of pregnenolone from cholesterol (figure 2), which 
give rise to progesterone. Dehydroepiandrosterone (DHEA)  and androstenedione are 
obtained from pregnenolone and progesterone, respectively. DHEA is then converted into 
androstenediol by 17β-hydroxysteroid dehydrogenase (HSDs; 17β-HSD-1, -7 and -12) and 
in androstenedione by 3β-hydroxysteroid dehydrogenase (3β-HSD-1). Androstenediol is 
converted into testosterone by 3β-HSD-1, whereas androstenedione is converted into 
testosterone by 17β-HSD-5. Finally, aromatase (CYP19) is responsible for  the conversion 
of androstenedione to estrone and of testosterone to 17β-estradiol (E2) (19, 20).  
 
 
 
Figure 2: Biosynthesis of estrogens.  
17β-HSD: 17β-hydroxysteroid dehydrogenase; 3β-HSD: 3β-hydroxysteroid dehydrogenase.  
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2.2. Aromatase 
Aromatase is a cytochrome P450 enzyme that is responsible by the biosynthesis of 
the estrogens, estrone and estradiol, being, therefore an important therapeutic target for 
breast cancer (21-23). This enzyme is found in the endoplasmic reticulum of cells 
producing estrogens, in particular, ovaries, placenta, testis, brain and skin (21, 24). The 
ovary is the organ where the aromatase concentrations are higher, in premenopausal 
women. While in postmenopausal women this enzyme has a higher expression in adipose 
tissue (21, 25, 26). The expression and activity of aromatase in adipose tissue increases 
with age, leading to the production of estrone (E1) and estradiol (E2) from 
androstenedione. The estrogen biosynthesis is regulated by paracrine interactions 
between malignant breast epithelial cells, fibroblasts and endothelial cells, promoting the 
expression of aromatase (21, 27). Women with breast cancer sometimes show 
desmoplasias resulting from the accumulation of fibrous tissue around the epithelial cells 
(21).  
As mentioned, the aromatase is an enzymatic complex composed by a cytochrome 
P450 and a NADPH-cytochrome P450 reductase (28) and is encoded by the CYP19A1 gene 
(29) present in chromosome 15q21.1 (30). The coding region of the aromatase gene is 
composed by nine exons and its expression is regulated by the activation of specific 
promoters (21, 22, 24), (figure 3). 
 
Figure 3: Aromatase Gene – CYP19 
 
The promoter I.1 is expressed in the placenta, the promoter II in ovaries and the 
promoters I.3 and I.4 in adipose tissue. Besides I.3, the tumor cells of breast cancer also 
express promoters I.7 and II (31).  Promoters I.f and I.6 are expressed in the brain and 
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bones respectively (32). There are also other factors that stimulate the expression of 
aromatase. The regulation of aromatase expression in the ovaries, is mediated by follicle-
stimulating hormone (FSH) through a cyclic AMP-dependent pathway, while in adipose 
tissue the promoter I.4 is regulated by cytokines, such as tumor necrosis factor (TNF-α) 
(33, 34). Activation of abnormal promoters in breast and fat tissues by the action of 
malignant epithelial cells will induce the expression of aromatase, what makes that its 
concentration is higher in women with breast cancer (21, 35-41). Promoters I.3 and II can 
be activated by prostaglandin E2 (PGE2) (42). The mRNA levels that encode the enzyme 
aromatase are significantly higher compared to normal tissue where only intervenes 
promoter I.4 (43).  
In 1987, Poulos et al presented a proposal for the structure of aromatase based on 
the similarity with the enzyme found in Pseudomonas putida (44), but, only in 2009, 
Ghosh et al were able to crystallize this enzyme from human placental microssomes (30) 
(figure 4). 
 
Figure 4: Tertiary structure of aromatase isolated from human placenta. Colored in dark blue is 
the N terminus, starting at residue 45, and colored in red is the C terminus ending at residue 496. The α-
helices are labelled from A to L and β-strands are numbered from 1 to 10. The heme group and the 
androstenedione molecule bound at the active site are also shown. Adapted from (30) 
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The tertiary structure of aromatase is constituted by 12 α helices and 10 β sheets 
(30). The androstenedione substrate binds to the heme iron localized in the aromatase 
active center by action of the carbon 19 resulting in two hydrogen bonds with Asp309 and 
Met374 residues (45) (figure 5). The supplementary cavity is formed by hydrophobic 
residues and porphyrin rings that contribute to the binding of enzyme-substrate. The 
Arg115 residues, Ile133, Phe134, Phe221, Trp224, Ala306, Thr310, Val370, Val373, Met374 
and Leu477 residues establish van der Waals bonds with androstenedione (30, 45). 
 
 
Figure 5: The active site of aromatase. Magenta shows the connection of androstenedione to the active 
center. Adapted from (45) 
 
2.3. Estrogen Receptors 
 
The discovery of a specific protein, in 1960, by Jensen and Jacobson, responsible 
for the response of estrogen in target tissues was denominated estrogen receptor (ER) 
(46). The estrogen receptor exists in two isoforms: ERα and ERβ (47-49) with a 56% 
homology between them (50). The ER belongs at a large family of nuclear receptors (16) 
and is synthesized by distinct genes (51), ESR1 and ESR2. The receptor alpha (ERα), 
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uncovered in 1962 (52), is considered one important receptor for the diagnostic of 
estrogen dependent breast cancer. The receptor beta (ERβ) was identified in 1996 (53) on 
prostate and ovaries of rats and on human testicle (54). However, its role in human breast 
cancer remains unclear (55).  
Estrogen receptors (ERs) play a decisive role in the development and function of 
the reproductive system and mammary gland (51) (figure 6) as well as in cancer 
development. ERα is expressed mainly in the liver, uterus and mammary gland, while in 
the lungs, kidneys, colon, gastrointestinal tract, there is a greater abundance of ERβ. In 
the ovaries, although both ERs are expressed, their cellular distribution is markedly 
different, since ERα is expressed mostly in the theca and interstitial cells, whereas ERβ is 
especially expressed in the granulosa cells (51).  
 
Figure 6: Distribution of ERα and ERβ by the different organs 
The clinical and in vitro studies allowed the understanding of the importance of 
these receptors in breast cancer disease (56). The α receptors are expressed in about 70% 
of breast tumors. Given the function of ER in regulating proliferation and differentiation 
of normal tissue, the study of cell signaling mechanisms is very important to control these 
processes in cancer situations. For this reason the ERα is used as a biomarker in the 
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progression of breast cancer and as an effective therapeutic target (51). Although the ERβ 
is present in fibroblasts of normal breast adipose tissue in ER positive breast cancer 
situations its expression decreases with tumor development, which  may be related to the 
potential of these receptors for anti-proliferative action (55). ERβ has a decisive function 
on the gene expression of several matrix mediators, like the proteoglycans syndecans-2/-4 
and serglycin, several matrix metalloproteinases, plasminogen activation system 
components and receptor tyrosine kinases (57).  
The human ERα is a 66 kDa protein that contains 596 amino acids (58) and is 
located on chromosome 6 (6q25.1) (59). The ERβ has 59 kDa, contains 530 amino acids 
(60) and is situated on chromosome 14 (14q23.2) (61) (figure 7). 
 
 
Figure 7: Schematic representation of the human ERα and ERβ structures. Both ERs are 
characterized by the A/B domain at the N-terminus, which contains the ligand-independent transcriptional 
activation domain (AF-1), the C domain that represents the DNA-binding domain (DBD) and contains a 
nuclear localization signal (NLS), the D domain, the E domain that harbors the ligand-binding domain (LBD) 
and the ligand-dependent transcriptional activation domain (AF-2) and lastly the F domain at the C-terminus. 
The percentage of homology for both ERs in relation to each domain is represented. 
 
As with other nuclear receptors, ERs have multiple domains consisting in six 
functional regions.  A A/B domain has the  ligand-independent activation function (AF-1) 
(51), a DNA-binding domain (DBD) the C domain, a dimerization region (DR), the D 
domain, a ligand binding domain (LBD), the E domain (58). The C domain has a structure 
that allows the dimerization of the receptor and subsequent binding to DNA target 
sequences (62). The D domain is a region, with only 30% of homology between the ERs. 
The E region contains the ligand binding domain (LDB), the second nuclear localization 
signal and a ligand-dependent transcription activation function (AF-2). Lastly, the F 
ER α
ER β
Domain/Homology
DRAF-1 DBD LBD/AF-2
AF-1 DBD LBD/AF-2DR
A/B
18%
C
97%
D
30%
E
47%
F
18%
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domain contains the C-terminus wich may be associated with dimerization processes or 
protein interaction (16, 51). 
 
2.4. Pathways of Estrogen Signaling  
Various studies conducted in the last years have elucidated the molecular gene 
expression mechanisms regulated by ERs (63). The signaling pathways activated by ERs 
depend on their intracellular localization, since ERs can be localized in nucleus, cytoplasm 
or in cytoplasmic membrane (64). There are two different mechanisms involved in the ER 
activation, the genomic and the non-genomic pathway (figure 8).  
The genomic pathway or NISS (nuclear-initiated steroid signaling) may occur in 
two ways, the classical and non-classical pathways. In the classic or direct mechanism, the 
estrogens that have crossed the cytoplasmic membrane by diffusion bind to the ER 
receptor, resulting in its dimerization and activation (65) and  allowing the translocation 
of ER to the nucleus. In the nucleus, in the presence of co-activators (CoA), it binds 
directly to specific regions of DNA, the estrogen response elements (ERE), located in the 
promoters of target genes (64). In the non-classic or indirect pathway, the ER binds 
indirectly to the DNA through other transcription factors, such as activation protein-1 
(AP-1) and specificity protein-1 (SP-1). In both pathways, depending on the cell stimulus, 
the binding of ER promotes the recruitment of co-regulators or co-repressors (63).  
The activation of the non-genomic pathway or MISS (membrane-initiated steroid 
signaling) induces a faster response than the genomic pathway (64). In the non-genomic 
pathway the ERs can also interact or activate other cell membrane receptors, such as the 
insulin-like growth factor receptor 1 (IGFR1), the epidermal growth factor receptor 1 
(EGFR1) and human epidermal growth factor receptor 2 (HER2). This interaction leads to 
activation of intra-cytoplasmic kinases, such as phosphatidylinositide 3-kinases (PI3K), 
mitogen-activated protein kinase (MAPK) and protein kinase B (AKT) (65).   
However, it is known that the genomic and non-genomic pathways are not 
completely independent, but, complementary and even synergistic (65). Several studies 
have demonstrated the occurrence of “cross-talk” mechanisms between the ER and the 
signaling pathways of EGFR / HER2 and of the IGFR1. Others studies showed that the G 
protein-coupled estrogen receptor (GPR30) can also induce the activation of EGFR (66). 
In addition, kinases can phosphorylate ER, co-activators and other transcription factors 
causing an increase in gene expression. These mechanisms of “cross-talk” between ER and 
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growth factors receptors (GFRs) promote cellular proliferation and progression of breast 
cancer, as well as the development of resistance to endocrine therapies (66, 67). 
 
 
 
Figure 8: Schematic representation of ER signaling pathways. In genomic signaling of ER, 
considering the classical pathway, the ER binds directly to the DNA, to the ERE region, recruiting co-
regulators. In the case of non-classical pathway, regulation and gene transcription occurs through receptor 
interactions with other classes of transcription factors such as AP-1. In the non-genomic signaling pathway the 
binding of E2 to the ER of citoplasmatic membrane associated to G protein or the binding of GF receptors will 
activate MAPK / AKT proteins, essential for cell proliferation. 
E2-estrogen; ER, estrogen receptor; CoA co-activators; GF-growth factor; EGFR- epidermal growth factor 
receptor; IGFR- insulin like growth factor receptor; ERE- estrogen-responsive elements; MAPK- kinase 
activated by mitogenic agents; AKT- protein kinase B; AP-1 Activator protein-1; GPR-30-G-protein coupled 
receptors. 
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3. Hormonal therapy in breast cancer treatment 
Treatment of breast cancer has advanced significantly in the recent decades (68). 
The chosen treatment plan depends mainly on the stage of disease, the type of tumor and 
the general health of the patient. In view of the needs of each patient it may be necessary 
to choose for one or even a combination of two or more treatments. Surgery and 
radiotherapy are considered local therapy, while the chemotherapy and hormonal therapy 
are examples of systemic therapy (69). 
Endocrine therapy is considered the standard treatment for the hormone 
dependent breast cancer (70). Estrogens have important functions in breast cancer, so the 
development of a treatment able to block the estrogen signalling is a mark in history of 
breast cancer. Actually, there are two therapeutic strategies used to reduce the action of 
estrogens on the target organs. The first is the use of ER modulators (SERMs), as 
tamoxifen, that modulate the binding of estrogens to ER and of selective ER 
downregulators (SERDs), as fulvestrant that down-regulate ER protein levels. The second 
strategy involves the aromatase inhibitors (AIs) that bock the conversion of androgens to 
estrogens by inhibition of the enzyme aromatase (3, 71, 72).  
 
3.1. Selective ER modulators (SERMs) and selective ER 
downregulators (SERDs) 
The SERMs are ER modulators that are partial agonists depending on the target 
tissue. In some cases have an agonistic effect while in others present an antagonistic 
activity. Tamoxifen was the first SERM approved through the U.S. Food and Drug 
Administration (FDA), in 1977, for treatment of breast cancer and in 1998 as quimio-
preventive agent for women with high risk of developing this disease (73). More recently, 
other SERMs were approved, as toremifen and rolexifen (figure 9). FDA approved 
raloxifen for prevention and treatment of osteoporosis and tamoxifen, toremifen and 
raloxifen as preventive and treatment for breast cancer (74).  
  
14 
 
 
Figure 9: Selective ER modulators (SERMs) 
 
Tamoxifen was the first endocrine therapy for breast cancer. It is prescribed for the 
treatment in premenopausal women for a period of at least five years, but it may be used 
in women after menopause supplemented with AIs. This drug is considered an antagonist 
in the breast tissues, since it blocks the action of estradiol, but also acts as an ER agonist in 
endometrium and bone, causing endometrial hyperplasia and increased risk of 
endometrial cancer, as well as the preservation of bone density in postmenopausal women 
(75). Tamoxifen was considered the treatment of choice during many years, because it can 
decrease by 50% the risk of recurrence. However, despite the demonstrated effectiveness, 
it can occur the development of resistance (74).  
SERDs, like Fulvestrant, are considered pure antiestrogens (76). Fulvestrant binds 
to estrogen receptors, leading to rapid degradation of the receptors (77, 78). Several 
studies in vitro have shown that fulvestrant was more effective than tamoxifen (79). 
Studies have demonstrated that SERDs are effective in patients previously treated with 
tamoxifen or AIs (80). The fulvestrant administration route is parenteral, allowing better 
monitoring of treatment adherence and reduces pharmacokinetic interference from oral 
administration, by interaction with food or other drugs. Although being  a good alternative 
for patients with advanced breast cancer when other endocrine therapies do not result, 
one cannot exclude the possible occurrence of resistance to fulvestrant in prolonged 
treatment situations (80). 
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3.2. Aromatase Inhibitors (AIs) 
Aromatase inhibitors are very effective in inhibiting estrogen synthesis and are 
divided into two groups based on their chemical structure and mechanism of action, the 
non-steroidal and steroidal inhibitors (81). Steroidal AIs compete with androstenedione 
and testosterone to the active site of the enzyme and establish an irreversible binding, 
resulting in the inactivation and degradation of the enzyme, and for this reason, are also 
called suicide inhibitors (82). The non-steroids bind reversibly to the enzyme. 
 
According the period of discovery and application, AIs can be divided as first-, 
second- and third-generation and each consecutive generation presented higher specificity 
to aromatase and lower adverse effects (83, 84). In 1980 in Europe, appeared the second 
generation aromatase inhibitors, formestane and fadrozol and a decade later, the use of 
the third-generation of aromatase inhibitors was approved. Currently, AIs used in clinic 
are those of the third generation, the non-steroidal, letrozole, anastrozole and the steroidal 
exemestane (83, 84). These have proven to be an alternative to tamoxifen for the 
treatment of ER+ breast cancer in postmenopausal women. It has been found further that 
this therapy allows a better quality of life in these women (21). Aromatase inhibitors are 
also effective in the treatment of breast cancer resistant to tamoxifen (21, 85). 
AIs showed to be advantageous for patients with breast cancer in postmenopause, 
because they are better tolerated and have a higher activity compared with tamoxifen (86). 
AIs inhibit cell proliferation causing retention in the cell cycle and apoptosis (87). This cell 
death is mediated by several mechanisms and regulated by the expression of different 
factors and proteins, especially of the Bcl-2 family (88). 
Although AIs are considered a good alternative to tamoxifen for the treatment of 
hormone-dependent breast tumors, some are resistant before the endocrine treatment, 
due to intrinsic resistance or  after an extended period acquired resistance may occur (89). 
Thus, it is crucial to understand the molecular mechanisms and characteristics of 
resistance to AIs and tamoxifen, to choose the most effective treatment (90).  
There are several mechanisms proposed to explain the resistance to endocrine 
treatment, namely the dysregulation of various components of the ER signaling pathway, 
including the loss of expression of ERα; the activation of pathways that may promote cell 
proliferation and survival alternative stimulus, via EGFR, PI3K/AKT/mTOR pathway; 
changes in cell cycle and apoptosis and alterations in the epigenetic and microRNAs 
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modulation. The resistance to endocrine therapy may also be associated with a decrease or 
absence of the ER function. 
Several other factors and pathway shave been referred to be involved in  endocrine 
resistance, like HER2, cyclin E1, the inducible hypoxia factors (HIF) and MAPK pathway 
(91). The activation of other non-classical pathways may influence the resistance to 
hormone therapy as they can lead to changes in the expression of co-activators, co-
repressors, and receptor tyrosine kinases (92). Relatively to AIs resistance there are 
differences between steroidal and nonsteroidal inhibitors. It is considered that the 
chemical structure of molecules and interaction with the active site of the enzyme may be 
one of the causes for the divergence in resistance behaviors (93). 
Treatment with AIs, especially with exemestane, anastrozole and letrozole, leads to a 
reduction in estrogen levels, causing a decrease in bone mass resulting in increased bone 
fragility, which can ultimately induce osteoporosis (94). This disease is induced by 
treatments leading to premature menopause, chemotherapy, ovarian suppression and 
anti-estrogen therapies, causing bone loss and an increased fracture risk in breast cancer 
survivors (BCS) (95-97) Several studies demonstrated that in the first 5 years of natural 
menopause, it occurs an estimated 0,5-3% annual bone loss (98). However, this bone loss 
is accelerated with cancer treatments, as the endocrine therapy with AIs, because they 
effectively deplete residual oestrogen levels (99, 100). This bone loss ranges from 1,6-7,4% 
per year (98, 101-103) and 1,5-3 times of these women have bone fracture (104-106), 
which are associated with functional decline, fall risk and varying degrees of morbidity 
(107). In order to control and prevent the effects of this adverse action of AIs it is 
necessary the use of supplementary therapy with bisphosphonates administration, 
calcium and / or vitamin D (108). 
Several studies show that treatment with these drugs leads to changes in 
cholesterol, triglycerides and glucose increasing the risk for cardiovascular diseases. In 
view of this data it is important to make a preliminary evaluation of other disorders such 
as heart failure, hypertension, arrhythmia, diabetes and obesity (109). Some studies 
indicate that therapy with AIs has fewer associated risks compared to tamoxifen, being 
better tolerated by patients (110). 
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3.2.1. Non-steroidal AIs 
The non-steroidal AIs or Type II (figure 10) establish a non-covalent binding with 
the heme portion of the aromatase causing the saturation of the binding site (83). 
Inhibition per this type of AI is reversible and depends on a constant supply of drug (82). 
Some studies have shown that, given the reversible nature of these inhibitors, the enzyme 
aromatase activity is recovered after treatment (111). 
Aminoglutethimide was the first AI used to endocrine treatment of breast cancer 
(82). Its introduction for therapeutic purposes occurred in 1960 as anticonvulsant, but, 
owing to the severe side effects, was withdrawn from the market by the FDA six years 
later. Its inhibitory capacity of aromatase, preventing the conversion of androgens to 
estrogens, was described in 1974 (112), however aminoglutethimide is unspecific and, 
therefore, can inhibit other CYP450 enzymes involved in the biosynthesis of other 
steroids, such as cortisol (113). In order to minimize the side effects of this inhibitor, its 
management was  done in combination with corticosteroids (89). 
Fadrozol a second generation AI (114), was more selective and potent, relatively to 
aminoglutethimide but also interferes with the biosynthesis of progesterone, aldosterone 
and corticosterone (115). Due to the lack of selectivity and to its adverse effects, this 
nonsteroidal inhibitor is not clinically used for the treatment of breast cancer, being 
replaced by the use of third generation non-steroidal AIs. 
Anastrozole (Arimidex ®) a third generation AI is very selective. This compound 
has a functional triazol group, which reversibly binds to the enzyme. This aromatase 
inhibitor has no progestogen, androgenic or estrogenic effect (116). It has an extensive 
hepatic metabolism by reactions of N-dealkylation, glucuronidation, and hydroxylation.  
After 72 hours of administration 10% of unchanged drug is excreted in the urine, while 
60% is excreted as metabolites (117). Anastrozole has two principal metabolites, the 
hydroxy-anastrozole and anastrozole-glucuronide (118). 
Anastrozole is indicated for the treatment of ER+ breast cancers in advanced or 
early stages. The recommended daily dose is 1 mg. Anastrozole reaches peak plasma 
concentrations 2 hours after oral administration. It is estimated that anastrozol has a time 
half-life of 50 hours (119). The combination of anastrozole with other treatments requires 
special care, especially in the case of tamoxifen. Some studies demonstrated that the 
interaction with tamoxifen leads to a decrease of about 27% of plasma concentrations of 
anastrozole, thus decreasing its effectiveness (118).  
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The most common side effects of treatment with anastrozole are weakness, 
generalized pain, hot flashes, arthralgia, and elevated serum cholesterol levels. Like 
exemestane and letrozole, anastrozole causes a decrease of bone density as a consequence 
of the suppression of estrogen. The occurence of bone fractures during treatment with 
anastrozole is superior relatively to the observed with tamoxifen treatment. In treatment 
with anastrozole there is a decrease in the occurrence of relapses relative to tamoxifen 
(117). The resistance to anastrozole is associated with a upregulation of PI3K/AKT 
pathway and IGF-1 receptor (120) 
Finally, letrozole (Femara ®) is the other highly selective third-generation AI, 
which has a mechanism of action similar to anastrozole (121). This inhibitor is specific for 
aromatase, so it causes no changes in plasma concentrations of other hormones during 
treatment (122). This AI is used in early or advanced stages. In addition, letrozole  is used 
for the treatment of patients with tumor progression after treatment with antiestrogens or 
in recurrence cases. Its administration is done orally at 2.5 mg daily (123) and it is rapidly 
and completely absorbed being widely distributed throughout the body. Letrozole has a 
half-life of 42 hours. The principal route of elimination is by via cytochrome P450, namely 
CYP3A4 and CYP2A6, with formation of inactive carbinol metabolites (124). 
The adverse effects at bone level is very similar to those for anastrozole, being 
necessary the previous evaluation of bone density. The combination of letrozole with other 
drugs is another factor to consider, since drug interactions can occur and, consequently, 
reduce letrozole efficacy. Comparative in vivo studies of other AIs have shown that 
letrozole, relatively to anastrozole evidenced greater effectiveness. During treatment with 
letrozole it may occur cardiovascular problems such as thromboembolism (124). 
Relatively to biological effects, Thiantanawat et al. demonstrated that both 
anastrozole and letrozole induced apoptosis  in breast cancer MCF-7aro cells by down- 
regulation of Bcl-2,  cyclin D1 and c-myc, up-regulation of Bax, p53 and p21 and activation 
of caspases-7, -9 and -6. These non-steroidal AIs caused a cell cycle arrest in G1-S phase 
transition (87, 125).  Moreover, other studies have shown that anastrozole and letrozole 
are better than fulvestrant in suppressing tumor growth (122).  
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Figure 10: Chemical structure of the non-steroidal AIs aminoglutethimide, fadrozol, 
anastrozole and letrozole 
 
3.2.2. Steroidal AIs 
One of the earliest steroidal AIs used in the treatment of breast cancer was 
testolactone (figure 11). This AI has a structure similar to testosterone. Studies have shown 
that testolactone administration is associated with a decrease in serum levels of estrone. 
This may explain the anti-tumor activity of this steroid inhibitor (126). 
The second-generation AI, the formestane or 4-hidroxiandrostenedione, is a 
selective, specific and effective AI. Formestane is administered intramuscularly, 200 to 
500 mg every two weeks (127), but this form of administration causes several adverse 
reactions especially at administration site and, because of that, formestane is no more 
used in clinic (128). 
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Exemestane, discovered in the United States, is the only steroid third generation AI 
(129), binds irreversibly to the active site of aromatase leading to its modification and 
degradation (130). Therefore, its administration significantly reduces estrogen levels. 
Exemestane (Aromasin ®) is prescribed for the treatment of postmenopausal 
women diagnosed with breast cancer ER+ in early or advanced stage and in situations 
whose progression occurred after treatment with antiestrogens. Clinical studies have 
shown that suppression of estrogen levels is achieved by oral administration of 25 mg 
daily, resulting in 98% inactivation of aromatase (131). An oral daily dose of exemestane is 
rapidly absorbed with maximum plasma concentrations achieved after 2 hours. Its half-
life is 27 hours, and then is eliminated by the liver and kidney (132). Its main metabolites 
are 17β-hydroexemestane and 6-hydroxymetylexemestane, which remain biologically 
active (133). The 17β-hydroexemestane metabolite has high affinity for the androgen 
receptor (AR) (84). In general, treatment with exemestane is successful, being possible to 
observe an improvement in clinical status and survival of patients diagnosed with breast 
cancer compared to tamoxifen treatment. 
Like all AIs, exemestane has adverse effects but compared to tamoxifen the 
occurrence of thromboembolism (100) and gynecological symptoms are lower (134). It 
was also shown that this AI does not have major impact on cholesterol and lipoproteins 
levels (135). Although some studies have demonstrated that it induced the occurrence of 
bone fractures, others indicated that given its androgenic effect, this AI causes less bone 
loss than anastrozole or letrozole (84). The occurrence of resistance is another side effect 
verified during the treatment with exemestane. The mechanisms involved are an increase 
on MAPK pathway activity (136), a decrease on expression of ER (137) and a promotion of 
cell cycle progression (138). 
In vitro studies demonstrated that exemestane induced antiproliferative effects in 
MCF-7aro cells, such as cell cycle arrest by blocking G0-G1 and G2-M phase transition and 
apoptosis. The latter was associated with loss of mitochondrial transmembrane potential, 
increase in caspases-9 and -7 activities and in reactive oxygen species (ROS) production. 
Moreover, this study showed that exemestane induced autophagy, though it was suggested 
that this process acted as a pro-survival mechanism (139). 
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Figure 11: Chemical structure of the steroidal AIs testolactone, formestane and exemestane 
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Aim of the study 
One of the therapeutic strategies for  estrogen receptor-positive (ER+) is the use of 
aromatase inhibitors (AIs) that inhibit the enzyme aromatase, which catalyzes the final 
step of estrogens biosynthesis.  
Although, the AIs used in clinic proved to be effective, they cause some serious side 
effects including bone loss and the development of resistance. For this, the search for 
novel potent compounds, with fewer side effects, is currently needed. In this sense, we aim 
to further study in breast cancer cell lines the effects of four new steroidal compounds (57, 
58, 59 and 60) selected from a series of compounds, synthesized from structural 
modifications on the aromatase substrate that previously demonstrated to be potent AIs in 
human placental microsomes. We intend to determine the anti-aromatase activity in 
breast cancer cells and study the biological effects of these  compounds in an ER+ 
aromatase-overexpressing human breast cancer cell line (MCF-7aro cells), and in an ER- 
human breast cancer cells (SK-BR-3) 
With this study we pretend to contribute to the understanding of the most 
favorable structure modifications in androstenedione in order to design/synthesize new 
steroidal compounds as potential AIs. Furthermore, this study can clarify the mechanisms 
involved in the inhibition of growth and induction of cell death of breast cancer cells using 
AIs and contribute to the development of more potent compounds with lower side effects. 
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1. Materials 
Eagles’s minimum essential medium (MEM), DMEM medium, fetal bovine serum 
(FBS), L-glutamine, antibiotic-antimycotic (10 000 units/mL penicillin G sodium, 10 000 
mg/mL streptomycin sulphate and 25 mg/mL amphotericin B), Geneticin (G418), sodium 
pyruvate and trypsin were supplied by Gibco Invitrogen Co. (Paisley, Scotland, UK). 
Testosterone (T), estradiol (E2), ethylenediaminetetracetic acid (EDTA), 
dimethylsulfoxide (DMSO), tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5- 
difenyltetrazolium (MTT), Höechst 33258, Casodex (CDX), propidium iodide (PI), Triton 
X-100, DNase-free RNase A, staurosporine (STA), charcoal, carbonyl cyanide m-
chlorophenylhydrazone (CCCP), 2′,7′-dichlorodihydrofluorescein diacetate (DCDHF2-
DA), phorbol 12-myristate 13-acetate (PMA), Trypan blue, protease inhibitor cocktail, 
Fluoroshield mounting medium, dextran and formestane were from Sigma–Aldrich Co. 
(Saint Louis, USA). Giemsa stain was purchased from Merck (Damnstadt, Germany). DPX 
mounting medium was from VWR (Radnor, PA, USA). Caspase-Glo® 3/7, Caspase-Glo® 
9 luminometric assays, Cyto-Tox 96 nonradioactive cytotoxity assay kit and Reporter Lysis 
buffer were from Promega Corporation (Madison, USA). [1β-3H] androstenedione was 
obtained from Perkin-Elmer (Boston, MA, USA) and liquid scintillation cocktail Universol 
from ICN Radiochemicals (Irvine, CA, USA). Bradford assay reagent was from Bio-Rad 
(Laboratories Melville, NY, USA). Exemestane was from Sequoia Research Products Ltd. 
(Pangbourne, UK). Z-VAD-FMK was from BD Biosciences Pharmingen (San Diego, CA, 
USA). Rabbit polyclonal β-tubulin, goat polyclonal CYP19, goat anti-rabbit IgG and mouse 
anti-goat IgG antibodies were from (Santa Cruz Biotechnology, CA, USA).  
 
2. Compounds 
In this work we focused on the biological evaluation of four new potential steroidal AIs 
(57, 58, 59 and 60) synthesized from structural modifications on the aromatase 
substrate, androstenedione. These compounds were synthesized by the Pharmaceutical 
Chemistry Group of the Faculty of Pharmacy, University of Coimbra and CNC.IBILI, 
University of Coimbra by the Profs. Carla Varela, Elisiário Tavares da Silva, Fernanda M.F. 
Roleira and Saul Costa. 
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3. Preparation of the AIs, Testosterone and Estradiol 
The AIs were dissolved in DMSO and stored at -80 ºC. Testosterone (T) and Estradiol 
(E2) were prepared in absolute ethanol at 10 μM and stored at -20 ºC. For each assay the 
stock solution of compounds was diluted with the cultured medium to obtain the final 
working concentrations.  
 
4. Cell cultures 
The ER+ aromatase-overexpressing human breast cancer cell line (MCF-7aro cells) was 
prepared by stable transfection of MCF-7 cells with human placental aromatase gene and 
Geneticin selection. Cells were grown in 75 cm2 culture flasks with Eagle’s minimum 
essential medium (MEM) with phenol-red supplemented with Earle’s salts, 10% heat-
inactivated fetal bovine serum (FBS), 1% of sodium pyruvate (1 mmol/L), 2 mmol/L of 
glutamine, 1% penicillin-streptomycin-amphotericin B and G418 (700 ng/mL). Three days 
before the experiments, MCF-7aro cells were cultured with 1% of sodium pyruvate (1 
mmol/L), 2 mmol/L of glutamine, 1% penicillin-streptomycin-amphotericin B in steroid-
free MEM without phenol red with 5% pre-treated charcoal heat-inactivated fetal bovine 
serum (CFBS) to prevent the estrogenic effects of phenol-red and the interference of 
steroids present in FBS. MCF-7aro cell line was kindly provided by Dr. Shiuan Chen from 
the Beckman Research Institute, City of Hope, Duarte, CA, U.S.A. 
The ER− human breast cancer cell line, SK-BR-3 (ATCC®), was maintained in MEM 
with phenol-red, supplemented with Earle’s salts, 1% of sodium pyruvate (1 mmol/L), 1% 
penicillin–streptomycin–amphotericin B, 2 mmol/L of glutamine and 10% heat-
inactivated fetal bovine serum (FBS).  
The human fibroblast cell line, HFF-1 (ATCC®), was maintained in DMEM without 
phenol-red, 10% heat-inactivated FBS, 1% sodium pyruvate (1 mmol/L) and 1% penicillin-
streptomycin-amphotericin B. 
The culture medium was renewed every three days and the cells were maintained at 37 
ºC and 5% CO2 atmosphere, to ensure that there is a significant cell proliferation and 
stable nutritional levels. After reaching 80 to 90% confluence, the cells were washed with 
PBS and detached with trypsin/EDTA 1 nM for 2 minutes at 37 ºC and 5% CO2 
atmosphere. After, the cells were centrifuged in culture medium with FBS or CFBS to 
inactivate trypsin at 260 xg and 4 ºC for 5 minutes. Finally, and depending on the culture 
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dishes, the cells were resuspended with the necessary amount of culture medium, and 
after homogenization, the cells were counted in a Neubauer chamber and cultured. The 
culture medium and drugs were refreshed every three days. 
 
5. Preparation of charcoal heat-inactivated fetal bovine serum (CFBS) 
FBS (500 ml) was incubated with 8 g of activated charcoal for 24 hours at room 
temperature, followed by successive centrifugations at 4000 xg for 15 min for removing 
the steroids present in FBS. Between each centrifugation the supernatants were filtered to 
eliminate charcoal particles. After the final centrifugation, supernatant was filtered by a 
vacuum system through a filter cellulose acetate with a 0.22 μm pore size aliquoted and 
kept at -20 ºC.   
 
6. Preparation of charcoal pellets 
Charcoal pellets were previously prepared by adding 1 mL of a solution constituted by 
0,5% of dextran and 5% of activated charcoal solution to eppendorf tubes and 
centrifugation at 14000 xg for 10 minutes. After the supernatant was discarded and the 
pellets were dry at 37 ºC overnight.  
 
7. In cell aromatase assay 
The inhibition of the activity of aromatase enzyme for each compound on MCF-7aro 
cells was determined according to the method of Thompson & Siiteri (140) and Zhou et al. 
(141) with some modifications. This assay is based on the use of [1β-3H] andro-4-ene-3,17-
dione as aromatase substrate. In this assay it was measured the tritiated water released 
from the substrate during the aromatization process. Each experiment included a negative 
control, which does not contain the potential inhibitors. Formestane (1 µM) and 
exemestane (10 µM) were used as a positive control. 
MCF-7aro cells were cultured in 24-well plates at a cell density of 1×106 during 3 days. 
After this time, the medium was removed and cells were washed two times with PBS. 
Then, it was added 500 nM of progesterone to suppress the activity of 5α-reductase that 
also uses androgen as a substrate, 50 nM of [1β-3H] androstenedione and 10 μM of 
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formestane, exemestane or of the new compounds to a final volume of 500 μl of MEM. 
The [1β-3H] androstenedione was the last component to be added. Cells were incubated at 
37 ºC and 5% CO2 atmosphere during 1 hour. 
After incubation, the aromatization reaction was stopped with 100 μL of 20% 
trichloroacetic acid. Then the supernatants were transferred to eppendorf tubes, 
previously prepared with a pellet of activated charcoal, followed by an incubation period of 
1 hour at room temperature. After centrifugation at 14000 xg for 10 minutes, 500 μl of 
supernatants were transferred to new eppendorf tubes with activated charcoal, 
homogenized and incubated for 10 minutes at room temperature. The tubes were 
centrifuged at 14000 xg for 10 min and the supernatant was transferred to clean 
eppendorfs followed by the last centrifugation cycle at 14000 xg for 5 min. To tubes 
contains 3 ml of scintillation cocktail it was added 300 μl of supernatant. The counts per 
minute were read in a scintillation counter (LS 6500, Beckman Instruments, CA, U.S.A.). 
Cells treated with 10 μM of formestane and exemestane were considered as positive 
control and untreated cells as control. This assay was performed in two independent 
experiments in triplicate for each compound. 
The cells grown on 24 wells plates were lysed with 500 μl of 0.5 N NaOH and 
incubated overnight at room temperature with stirring to extract the proteins to 
quantification. Cells were then freezed at -80 ºC. The protein content was quantified by 
the Bradford method and used to normalize the radioactivity determined per μg of 
protein. 
 
8. Cell viability assay 
The effects of each steroidal compound (57, 58, 59 and 60) on cell viability of MCF-
7aro, SK-BR-3 and HFF-1 cell lines was determined by measuring the mitochondrial 
reductases activities using the tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-
difenyltetrazolium bromide (MTT) that forms a blue formazan precipitate.  Thereby, this 
colorimetric assay provides a percentage of cells capable to convert MTT to formazan. The 
cells were cultured in 96-well plates and incubated during 3 and 6 days with different 
concentrations of each compound. Untreated cells were used as control.  
MCF-7aro cells were cultured at a cellular density of 2x104 and 1x104 cells/mL (for 3 
and 6 days, respectively), in MEM without phenol-red with 5% CFBS and 1 nM of T or 1 
nM of E2. SK-BR-3 cells were cultured at a cellular density of 2.5x104 and 1x104 cells/mL 
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(for 3 and 6 days, respectively), in MEM with phenol-red containing 10% FBS . HFF-1 cells 
were cultured for 6 days at a cellular density of 7.5x103 cells/mL in DMEM without 
phenol-red containing 10% FBS. After the incubation period (3 or 6 days) it was added 20 
μL of MTT (0.5 mg/mL) per well and cells were incubated during 2 hours and 30 minutes 
in optimal conditions for growth. After this time, the medium was removed and it was 
added 200 μL DMSO: isopropanol mixture (3:1), to stop the reaction and dissolve the 
purple formazan precipitated, for 20 minutes with agitation at room temperature. The 
formazan was quantified spectrophotometrically at 540 nm.  
The cytolitic effects of each steroidal compound were evaluated in MCF-7aro cell 
line using the lactate dehydrogenase (LDH) assay. It is a cytosolic enzyme that is only 
released from cells to the culture medium after membrane disruption. LDH activity was 
measured using a LDH KIT (CytoTox 96 Non-Radioactive Cytotoxicity Assay, Promega 
Corporation) according to manufacturer’s protocol. This assay was performed in the same 
experimental conditions described for the MTT assay.   
 
9. Western blot analysis 
MCF-7aro cells were cultured in 6-well plates at a cellular density of 6x105 cells/mL 
during 3 days in MEM with red phenol. Then, cells were treated with each compounds (10 
μM) and incubated during 8 hours. After the incubation period, cells were washed two 
times with PBS and lysed with RIPA buffer (50 mM Tris-HCl, 1% Triton X-100, 0.1% SDS, 
150 mM NaCl, 2 mM EDTA, 0.5% Na-deoxycholate, pH 7.4) and 1% of a protease 
inhibitors cocktail.  After, cells were scrapped and collected to eppendorf tubes and 
centrifuged at 14000 xg for 10 minutes at 4 ºC. Protein concentrations were determined 
using the Bradford assay. A total of 50 μg of protein per sample was loaded on 10% SDS-
polyacrylamide gels and transferred to nitrocellulose membranes in 25 mM Tris-HCl, 250 
mM glycine and 18% methanol.  The membranes were blocked with 5% milk in TBS 
TWEEN (1x) during 1 hour. Immunodetection was performed using goat polyclonal 
antibody anti-CYP19 (1:100) (Santa Cruz Bio Technology, Inc.) in blocking solution 
overnight at -4 ºC. The secondary rabbit anti-goat antibody (1:2000) was incubated for 1 
hour. Membranes were exposed to chemiluminescence substrate Super Signal West Pico 
and then visualized by Chemidoc Touch Image (BioRad, Laboratories Melville, NY, USA). 
Membranes were then stripped and incubated with rabbit polyclonal anti-β-tubulin 
antibody (1:500) followed by goat anti-rabbit IgG secondary antibody (1:1000), to control 
loading variations. Untreated cells were used as control. 
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10. Morphological studies 
The morphological alterations in MCF-7aro cells caused by each compound (57, 58, 
59 and 60) were studied by phase contrast microscopy and by Giemsa and Hoescht 
staining. The cells were cultured in 24-well plates with coverslips at a cellular density of 
2x105 and 1x105 (for 3 and 6 days, respectively) in MEM without phenol-red containing 5% 
CFBS plus 1 nM of T. After 24 h, cells were incubated with each steroidal compound at the 
concentration of 10 μM.  
For Giemsa staining, cells were washed with PBS, fixed with methanol during 25 
minutes at 4 ºC and washed twice with PBS. After, the cells were stained with Giemsa 
diluted in PBS (1:10) for 30 minutes. After incubation the stained cells were washed with 
water and the coverships were mounted with DPX and observed on a bright field 
microscope (Eclipse E400, Nikon, Japan) equipped with the image analysis software 
LeicaQwin.  
The other assay used to evaluate the alterations in nuclear morphology namely 
chromatin fragmentation and condensation was the Hoescht staining. The cells were fixed 
with 4% paraphormaldehyde for 20 minutes at 4 ºC, washed twice with PBS and exposed 
to 0.05 μg/mL of Hoechst 33258 staining for 20 minutes. After several washings, 
coverslips were mounted with Fluoroshield mounting medium. Cells were observed under 
a fluorescence microscope (Eclipse Ci, Nikon, Japan) equipped with an excitation filter 
with maximum transmission at 360/400 nm and images were processed by Nikon NIS 
Elements image software.   
 
11. Cell cycle analysis 
This technique is used to evaluate the effect of the compounds on cell cycle 
progression. The cells were cultured in 6-well plates at a density of 7x105 cells/mL in MEM 
without phenol red containing 5% CFBS. After 24 hours, the cells were incubated with 
different compounds (10 μM) plus 1 nM of T for 3 days. Untreated cells were used as 
control.  
After the incubation period the medium was collected to recover the unadherent cells. 
Cells were washed with PBS. Then, they were trypsinized with 2.5% trypsin/EDTA 1 mM 
and transferred to separate centrifuge tubes containing 1 mL of culture medium with 5% 
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CFBS. Next, were centrifuged at 260 xg for 6 minutes at 4 ºC and supernatant was 
rejected. Cells were resuspended and fixed in 70% cold ethanol and stored at 4 ºC for 24 
hours. After this period, fixed cells were centrifuged at 260 xg for 6 minutes at 4 ºC (3 
times). The supernatant was discarded between each centrifugation, and the pellet was 
ressuspended in PBS. The last stage of this procedure was the addition of a DNA staining 
solution of 5 μg/mL of PI, 0.1% Triton X-100, 200 μg/mL DNase-free RNase A in PBS, to 
a final volume of 500 μL, and incubation overnight at 4 ºC. PI is a fluorescent dye that 
intercalates nucleic acids, enabling DNA content determination. Permeabilization of 
membranes was achieved by using Triton X-100. Degradation of RNA present by DNase-
free RNase A ensures that in the sample is present only DNA. The analysis was performed 
by flow cytometry and based on the acquisition of 40 000 events/cells in BD Accuri™ C6 
cytometer (San Jose, CA, U.S.A), equipped with BD Accuri™ C6 analysis software. The 
forward scatter (FSC) and side scatter (SSC) detectors and the three fluorescence 
channels (FL-1 (green), FL-2 and FL-3 (red)) were set on a linear scale. The results were 
indicated by the percentage of cells in the different cell cycle phases. Assays were 
performed in triplicate and in three independent experiments. 
 
12. Cell death analysis 
 
12.1. Caspase activity 
In order to study the involvement of apoptosis, caspase activities were evaluated by 
the Caspase-Glo® 3/7, Caspase-Glo® 9 luminescence assays. These enzymes are members 
of the cysteine aspartic acid-specific protease family and play key effector roles in 
apoptosis. Caspase 3/7 activation is used as an indicator of occurrence of apoptosis, 
however in the cell line used in the study it was only evaluated the activity of caspase-7 as 
this cell line does not express caspase-3. Caspase-9 plays a key role in the intrinsic 
apoptotic pathway.  
Cells were cultured in 96-well white plates at a cellular density of 2x104 cells/mL in 
MEM without phenol-red containing 5% CFBS. After 24 hours, cells were incubated with 
the compounds (1-25 μM) and 1 nM of T for 3 days. Untreated cells plus 1 nM of T were 
used as control. After treatment, the Caspase-Glo® 3/7 or -9 luminescent assay was used 
according to manufacturer’s instructions. As a positive control, cells were incubated with 
staurosporine (STA) (10 mM) for 3 hours. Z-VAD-FMK (50 mM), a pan-caspase inhibitor, 
was used as a negative control. The resultant luminescence was measured in a 96-well 
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Microplate Luminometer (BioTek Instruments, USA) and presented as relative light units 
(RLU). Three independent experiments were performed in triplicated. 
 
 
12.2. Intracellular reactive oxygen species (ROS) 
In order to study the levels of intracellular reactive oxygen species (ROS) the 2’, 7’-
dichlorodihydrofluorescein diacetate (DCFH2-DA) method was used. This is a lipophilic 
non-fluorescent compound that can cross the cell membrane and through the action of 
intracellular esterases is deacetylated to 2’, 7’-dichlorodihydrofluorescein (DCHF2), which 
reacts with intracellular ROS and is then oxidized into the final compound involved in this 
assay, the fluorescent compound 2’, 7’-dichlorofluoresceinn (DCF).  
The cells were culture in 96-well dark plates at a cellular density of 2 x 104 cells/mL in 
MEM without phenol-red containing 5% CFBS. After 24 hours, cells were incubated with 
the compounds (1-25 μM) and 1 nM of T during 3 days. Untreated cells plus 1 nM of T 
were considered as control. Cells were incubated for 2 hours with a positive control, the 
phorbol 12-myristate 13-acetate (PMA) at 25 ng/mL and labeled with 50 μM of DCFH2-
DA for 1 hour at 37 ºC. The fluorescence was measured using an excitation wavelength of 
480 nm and an emission filter of 530 nm, in a 96-well microplate luminometer (Synergy 
HT, BioTek, USA). The results were presented as mean fluorescence intensity (MFI). All 
assays were performed in triplicate and in three independent experiments. 
 
13.  Statistical analysis 
For statistical analysis it was used GraphPad Prism software 7. Analysis of variance 
(ANOVA) was followed by Bonferroni multiple comparisons test. P values <0.05 were 
considered statistically different. The data presented were expressed as the mean ± SEM 
(standard error of the mean). 
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1. Evaluation of aromatase inhibition 
In order to explore the anti-aromatase activity of the new compounds in breast cancer 
cells, it was performed the cell aromatase assay. MCF-7aro cells were treated with the 
compounds 57, 58, 59 and 60 and the tritiated water released from the [3H] 
androstenedione during the aromatization reaction was determined to evaluate the anti-
aromatase activity. All the compounds induced a drastic decrease in aromatase activity, 
showing that these new steroids are potent AIs in this aromatase overexpressing breast 
cancer cell line (figure 12).  
Compound 58 is the most potent AI with 98% of inhibition, being this inhibition 
similar to the reference AIs used, formestane and exemestane. Compound 57 caused a 
94% of inhibition, compound 60 a 89% of inhibition and compound 59 a 90% of 
inhibition.  
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Figure 12: Aromatase activity in MCF-7aro cells. Cells were treated with the steroidal compounds 
(57, 58, 59 and 60) at 10 μM. Formestane (F) and Exemestane (Exe) were used as a reference AIs. Data 
are presented as a percentage of the tritiated water release in relation to control cells (100%) and 
correspond to two independent experiments performed in triplicate. 
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2. Cell viability assay in HFF-1 cell line 
In order to understand the effects of these compounds on a non-cancerous cell line 
and its cytotoxic behavior it was evaluated the cell viability of HFF-1, a human fibroblast 
cell line, by MTT assay, after 6 days of treatment. The compounds (1-25μM) did not induce 
a significant reduction in cell viability (figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Effects of steroidal compounds on HFF-1 cell viability analysed by MTT. HFF-1 cells 
were treated with different concentrations of compounds (1-25 µM) during 6 days. Compounds caused no  
significant reduction in cell vibility. Cells cultured withouth treatment were considered as controls. Results 
are the mean ± SEM of three independent experiments done in triplicate. 
  
39 
3. Effects on MCF-7aro cell viability  
The effects of AIs in MCF-7aro cell viability were studied by MTT and LDH assays. The 
cells were incubated with the compounds 57, 58, 59 and 60 (1-50 μM) and stimulated 
with T (1 nM) during 3 and 6 days. As shown in figure 14, all the compounds induced a 
significant (p<0,01; p<0,001; p<0,0001) decrease in cell viability in a dose- and time-
dependent manner.  
 
 
 
 
 
 
 
 
 
 
 
The compounds 57 and 60 were the most effective in reducing cell viability, 
especially for higher concentrations. To evaluate if this decrease in cell viability was 
associated with membrane disruption it was determined the lactate dehydrogenase (LDH) 
activity in the cell culture medium. As illustrated in figure 15, except for compound 60 at 
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Figure 14: Effects of steroidal compounds on MCF-7aro cell viability analysed by MTT. MCF-
7aro cells were stimulated with Testosterone (T) and treated with different concentrations of compounds (1-
50 µM) during 3 and 6 days. Cells cultured with T were considered as controls. All the compounds induced a 
reduction in cell viability. Results are the mean ± SEM of three independent experiments done in triplicate. 
Significant differences between the control and treated cells are denoted by ** (p < 0.01), *** (p < 0.001) 
and **** (p < 0.0001). 
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50 μM, that caused a significant (p<0,001) increase in LDH release, the other compounds 
did not cause membrane disruption. Thus from now on it was only used concentrations 
lower than 50 µM. 
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Figure 15:  Effects of steroidal compounds on MCF-7aro cell membrane integrity analysed by 
LDH assays. MCF-7aro cells were stimulated with testosterone (T) and treated with different 
concentrations of compounds (1-50 µM) during 3 and 6 days. Cells cultured with testosterone (T) were 
considered as controls. Any of the compounds caused LDH release. Results are the mean ± SEM of three 
independent experiments done in triplicate. Significant differences between the control and treated cells are 
denoted by *** (p < 0.001). 
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4. Characterization of the mechanism of AIs action: dependence on 
aromatase and androgen-receptor 
In order to understand if the effects on MCF-7aro cell viability were dependent on 
aromatase, the cells were incubated with different concentrations of compounds in the 
presence of E2, during 3 and 6 days (figure 16). The results were compared with the ones 
obtained with T treatment. All compounds induced a decrease in E2-treated cells viability 
and it was concluded that compounds 57, 59 and 60 are aromatase independent, because 
the effects are similar to the obtained with T. However, compound 58 is aromatase 
dependent as the results obtained with E2 treatment are significantly different from the 
results with T (figure 17).  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Effects of steroidal compounds on viability of E2-treated MCF-7aro cells, analysed 
by MTT. MCF-7aro cells were stimulated with Estradiol (E2) and treated with different concentrations of 
compounds (1-25 µM) during 3 and 6 days. Cells cultured with E2 were considered as controls. All the 
compounds induced a reduction in cell viability of E2-treated cells. Results are the mean ± SEM of three 
independent experiments done in triplicate. Significant differences between the control and treated cells are 
denoted by ** (p < 0.01) and **** (p < 0.0001). 
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It was also used an antagonist to androgen receptor (AR), Casodex (CDX), to verify if 
the effects of compounds were dependent on AR. MCF-7aro cells were treated with T and 
CDX and incubated with the different concentrations (1-25 μM) of compounds, during 3 
and 6 days (figure 18). All the compounds induced a decrease in viability of CDX-treated 
cells. Moreover, by comparison with the results obtained with T-treated cells, it was 
observed that only compound 58 caused a significant difference in cell viability between 
treatments (figure 19) indicating an androgen-dependent effect.  
Figure 17: Comparison of the effects of compounds 57, 58, 59 and 60 (1 -25 µM) in viability of 
MCF-7aro cells stimulated with testosterone (T) or estradiol (E2), during 6 days. Compounds 
57, 59 and 60 induced a reduction in MCF-7aro cell viability in an aromatase-independent manner, while 
compound 58 caused an aromatase-dependent effect Results are the mean ± SEM of three independent 
experiments done in triplicate. Significant differences between the E2-treated versus T-treated cells are 
denoted by * (p < 0.05). 
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5. Cell viability T-treated versus E2-treated MCF-7aro cel 
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Figure 18: Effects of steroidal compounds on CDX-treated MCF-7aro cells viability analysed 
by MTT. MCF-7aro cells were incubated with Casodex (CDX) and treated with different concentrations of 
compounds (1-25 µM) during 3 and 6 days. Cells cultured with T + CDX were considered as controls. All the
compounds induced a reduction in cell vibility. Results are the mean ± SEM of three independent 
experiments done in triplicate. Significant differences between the control and treated cells are denoted by * 
(p < 0.1), ** (p < 0.01), *** (p < 0.001) and **** (p < 0.0001). 
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5. Western blot analysis 
To better understand the dependence on aromatase it was analysed, by western blot 
assay, the aromatase expression. The results showed that as exemestane, only compound 
58 induced a significant (p < 0,01) decrease in aromatase levels. These results suggest that 
this AI may cause aromatase degradation (figure 20). 
 
 
 
 
 
Figure 19: Comparison of the effects of different concentrations of compounds 57, 58, 59 and 
60 (1 -25 µM) in viability of MCF-7aro cells stimulated with testosterone (T) and with or 
without Casodex (CDX), during 6 days. Only compound 58 caused an AR-dependent effect. Results 
are the mean ± SEM of three independent experiments done in triplicate. Significant differences between 
the T-treated versus CDX-treated cells are denoted by * (p < 0.05), **** (p < 0.0001). 
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6. Cell viability in E2-treated MCF-7aro cells versus SK-BR-3 cells 
 To understand if the effects of the compounds were dependent on estrogen-receptor 
(ER) it was used an ER− human breast cancer cell line, SK-BR-3. For that, the cells were 
incubated with compounds 57, 58, 59 and 60 (1-25μM), during 3 and 6 days and the 
results compared with E2-treated MCF-7aro cells. Cells incubated without compounds 
were used as control.  
 
 
 
 
 
Figure 20: Western Blot analysis of Aromatase. MCF-7aro cells were treated with 10 µM of 
compounds during 8 hours. Exemestane (10µM) was used as a reference AI. Results are the mean ± SEM of 
three independent experiments done in triplicate. Significant differences between the control and treated 
cells are denoted by ** (p < 0.01), and **** (p < 0.0001). 
Aromatase 
β-Tubulin 
Co
ntr
ol 57 58 59 60
Ex
em
es
tan
e
0.0
0.5
1.0
1.5
Control
57
58
59
60
Exemestane
**
****
N
o
rm
a
liz
ed
 
R
el
a
tiv
e 
D
en
si
ty
:
A
ro
m
a
ta
se
/T
u
bu
lin
58 kDa 
55kDa 
  
46 
 
As shown in figure 21, all the compounds induced a significant decrease in SK-BR-3 cell 
viability. Although, by comparing the effects in MCF-7aro cells incubated with E2 with the 
results obtained in SK-BR-3 cells, it was concluded that all compounds decreased MCF-
7aro cell viability in an ER-dependent manner, since significant differences between 
treatments were observed (figure 22).  
 
 
 
 
 
 
 
 
Figure 21: Effects of steroidal compounds on SK-BR-3 cell viability analysed by MTT. SK-BR-3 
cells were treated with different concentrations of compounds (1-25 µM) during 3 and 6 days. All the 
compounds induced a reduction in cell vibility. Cells cultured without icubation with compounds were 
considered as controls. Results are the mean ± SEM of three independent experiments done in triplicate. 
Significant differences between the control and treated cells are denoted by * (p < 0.1), ** (p (p < 0.01), *** 
(p < 0.001) and **** (p < 0.0001). 
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7. Morphological studies 
To evaluate the morphological alterations induced by the compounds, MCF-7aro 
cells stimulated with T were treated with each steroidal compounds (10 μM) after 3 and 6 
days, and observed in phase contrast microscopy, and after Giemsa and Hoechst staining 
(Figure 23). 
After 3 and 6 days of treatment it was observed that all steroids caused a decrease 
in cell density and some morphological alterations, like membrane blebing, as observed by 
contrast phase microscopy, as well as chromatin condensation and fragmentation, typical 
features of apoptosis, observed after Giemsa and Hoechst staining. These morphological 
alterations were more evident after 6 days of AIs treatment (figure 23). In addition, the 
chromatin fragmentation was more evident for compound 57.   
Figure 22: Comparison of the effects of compounds 57, 58, 59 and 60 (1 - 25 µM) in viability of 
MCF-7aro cells stimulated with Estradiol (E2) and in SK-BR-3 cells, during 6 days. Compounds 
induced a reduction in viability of MCF-7aro cells in a estrogen-dependent manner. Results are the mean ± 
SEM of three independent experiments done in triplicate. Significant differences between the E2-treated 
cells and SK-BR-3 cells are denoted by &(p < 0.05), &&(p < 0.01), &&&(p < 0.001), &&&&(p < 0.0001). 
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Figure 23: Effects of compounds 57, 58, 59 and 60 (10 µM) on MCF-7aro cells morphology 
after 6 days of treatment cells. Analyzed by phase contrast microscopy (A), Giemsa (B) and Hoechst (C) 
stainings, presented a decrease in cell density and some morphological alterations typical of apoptosis, such 
as chromatin condensation and fragmentation (filled arrows). Original magnification x400. 
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8. Cell cycle analysis 
As the deregulation of the cell cycle and, consequently, lack of proliferation are 
possible mechanisms responsible for the effects of AIs on MCF-7aro cell viability, it was 
analyzed the cell cycle progression by flow cytometry after PI staining. PI is a fluorescent 
dye that intercalates DNA. According to the DNA content, it is possible to evaluate the 
distribution of cells in the correspondent cell cycle phases. 
Results demonstrate that all the AIs caused a significant (p < 0,0001) cell cycle arrest 
in G0/G1 phase, after 3 days of treatment, with a consequent decrease in S and G2/M 
phases (figure 24; table 1). Compound 57 was the less potent one. 
 
Table 1 - Effects of the different treatments on cell cycle in MCF-7aro cells for 3 days of incubation 
Cell Cycle G0/G1 S G2/M 
Testosterone 73.34 ± 0.96  6.99 ± 0.37 19.72 ± 0,90 
T + 57 79.38 ± 0.19 **** 4.08 ± 0.43 * 16.61 ± 0.35 * 
T + 58 83.64 ± 0.52 **** 2.75 ± 0.30 *** 13.62 ± 0.56 **** 
T + 59 85.92 ± 1.13 **** 2.00 ± 0.20 **** 12.00 ± 0.85 **** 
T + 60 82.20 ± 0.53 **** 2.67 ± 0.19 **** 15.26 ± 0.41 **** 
 
 
 
 
 
 
 
 
 
Figure 24: Effects of compounds on MCF-7aro cell cycle progression. Cells were treated with AIs 
(10 μM) plus T (1 nM), during 3 days and subjected to flow cytometric analysis after PI staining. Cells 
cultured with T were considered as control. Data represents means and SEM of of two independent 
experiments done in triplicates.  Significant differences between the control T versus treated cells are 
indicated by * (p < 0.05), *** (p < 0.001) and **** (p < 0.0001). 
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9. Cell death analysis 
As previously mentioned, these new AIs caused some morphological alterations typical 
of apoptotic mechanisms. Thus, to confirm these results the evaluation of caspase-7 and -9 
activities was performed. As shown in Figure 25 all compounds induced a significant (p < 
0,05; p < 0,001; p < 0,0001) increase in the activity of the initiator (-9) and of the 
executioner (-7) caspases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As there was an increase in the activity of the initiator caspase-9, suggesting the 
involvement of the mitochondrial pathway, the production of reactive oxygen species 
(ROS) was also determined. As shown in figure 26, none of the compounds induced ROS 
generation. Curiously, for AI 60 it was observed a significant decrease in ROS production. 
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Figure 25: Activation of caspase-7 and -9 in MCF-7aro cells treated with AIs (10 μM) after 3 
days of incubation. MCF-7aro cells cultured with T were considered as control. The cells treated with STS 
(10 µM) were considered as positive control. Results are presented as relative luminescence units (RLU) and 
correspond to the mean ± SEM of three independent experiments done in triplicate. Significant differences 
between the control T versus treated cells are indicated by * (p<0.05) *** (p < 0.001) and **** (p < 0.0001).  
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Figure 26: Formation of ROS in MCF-7aro cells treated with compounds after 3 days. Cells 
cultured with T were considered as control and cells treated with PMA were considered as a positive control 
for ROS production. The results are presented as mean fluorescence intensity (MFI) and correspond to 
mean ± SEM of three independent assays done in triplicate. Significant differences between the control T 
versus treated cells are indicated by *** (p < 0.001). 
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Estrogens play an important role in breast tumor growth due to the presence of a 
functional ER, which is expressed in 70-80% of these breast cancers cases (142). So a 
therapy that blocks the actions of estrogens and ER, as the endocrine therapy, is an 
important strategy for the treatment of this disease. During many years the tamoxifen was 
considered the standard therapy for pre- and postmenopausal women with breast cancer. 
However, in the last decades, the third-generation AIs are used in clinic to treat post-
menopausal women as well as pre-menopausal women with breast cancer after ovary 
function supression. Nevertheless, the development of endocrine resistance and 
occurrence of bone loss are some drawbacks that limit the AIs success. Several strategies 
are being performed in order to overcome these disadvantages as the search and 
development of new compounds, more powerful and with lower side effects (143-145). In 
this way, the aim of this study was to understand the anti-tumor properties of four new 
steroidal compounds (57, 58, 59 and 60), selected from a series of new steroidal 
molecules derived from androstenedione. To achieve this goal it was investigated their 
anti-aromatase activity and their in vitro biological effects.  
The selected compounds (57, 58, 59 and 60) presented high aromatase inhibition 
in placental microsomes. The majority of the studies were performed in a human breast 
cancer cell line that overexpresses aromatase, the MCF-7aro cells, a good model to study 
AIs in ER+ breast tumors (125). In this study it was observed that all the four new 
compounds have an anti-aromatase activity superior to 80% in MCF-7aro cells, being 58 
the most potent and the 60 the less potent AI. As all the compounds inhibit efficiently 
aromatase in breast cancer cells it was investigated their anti-tumor properties. As these 
compounds did not affect the viability of the non-cancerous fibroblastic cell line, HFF-1, it 
was evaluated their effects in MCF-7aro cells. All the compounds decreased the MCF-7aro 
cells viability. The compounds 57 and 60 were the ones that caused a more pronounced 
effect. Similar actions were also previously observed  for exemestane (139) and for other 
AIs synthesized by our group (146, 147). In order to understand if these biological effects 
were dependent or independent on aromatase or AR, the effects of each AI were also 
studied in MCF-7aro cells treated with E2, the product of the aromatization reaction, or 
with Casodex (CDX), an AR antagonist. To understand the dependence of these 
compounds on ER, the results of MCF-7aro cells stimulated with E2 were also compared 
to the results obtained for the SK-BR-3 cell line, a breast cancer cell line that 
demonstrated to be a good model for hormone-independent (ER-) breast cancer, since 
they do not expresse ERα (148). Only compound 58 caused an aromatase-dependent 
effect like the other steroidal AI used in clinic, exemestane (133) and also an AR- and ER-
dependent effect. All the other compounds were only ER-dependent. Previous studies 
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demonstrated that exemestane by inactivation and degradation of aromatase by 
proteasome, induced a reduction in aromatase expression (149), effect that justifies the 
aromatase-dependent action of exemestane (133, 149). In this way, in order to understand 
if AIs action were due to a similar cellular mechanism, it was evaluated, by Western Blot, 
the aromatase expression on MCF-7aro cells. As expected a decrease in aromatase 
expression was only observed for the compound 58.  
Moreover, MCF-7aro cells treated with the new molecules presented a reduction in 
cell density and morphological alterations, such as membrane blebbing, chromatin 
condensation and nuclear fragmentation, features of apoptosis. Therefore, as the decrease 
in cell viability may be due to anti-proliferative effects or  cell death it was carried out cell 
cycle analysis and evaluation of caspases activities. The results revealed that all the AIs 
caused cell cycle arrest in G0/G1 phase. Thus, it is possible to conclude that these new AIs 
have anti-proliferative effects in MCF-7aro cells. Studies performed for other AIs, 
including letrozole, anastrozole, exemestane (87, 139) and other steroidal AIs synthesized 
by the group (143, 146, 147), also showed that these compounds induced cell cycle arrest of 
ER+ breast cancer cell lines overexpressing aromatase. 
In addition, as one of the mechanisms that may be linked to the observed reduction 
of cell viability is the occurrence of apoptosis, it was explored the involvement of this 
phenomenon by evaluating the activation of caspase-7 and -9. All compounds caused a 
significant increase in caspase-7 activity in MCF-7aro cells, confirming the involvement of 
an apoptotic process. Compound 60 was the AI that presents a greater caspase-7 
activation, wich was associated to the most drastic effects observed on MCF-7aro cell 
viability. As it was well discribed, apoptosis can occur by the mitochondrial pathway, 
which is characterized by a mitochondrial membrane permeabilization and subsequent 
activation of caspase-9, or by death receptor pathway, in which caspases are activated 
upon ligand binding to the death receptors. However, as our previous studies indicated 
that steroidal AIs induced apoptosis through the mitochondrial pathway, it was 
investigated the involvement of the intrinsic/mitochondrial pathway in the apoptotic 
process by evaluation of caspase-9 activity. All the AIs induced an increase of caspase-9 
activity, suggesting the occurrence of an intrinsic apoptotic process.  
As the production of ROS can lead to a state of oxidative stress that may be 
associated to mitochondrial dysfunction and apoptosis (150) it was evaluated the levels of 
ROS production. However, our data indicated that the activation of the intrinsic apoptotic 
pathway was ROS-independent. Curiously, AI 60 caused a decrease in ROS production, 
suggesting a potential protective effect probably due an antioxidant effect. Nevertheless, 
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as this AI was the one that caused a drastic reduction in MCF-7aro cell viability these 
results may also be due to the reduction of viable cells and, consequently, to lower ROS 
production (139). Nevertheless, further studies must be performed in order to better 
understand this effect. 
In summary, the characterization of these four new steroidal compounds in terms 
of aromatase inhibition, biological effects and anti-tumor efficacy in a breast cancer cell 
model indicated that all the compounds were potent AIs and decreased the viability of 
MCF-7aro cells, a hormone-dependent breast cancer cell line without causing any effect on 
fibroblastic non-tumor cells. The results showed that compound 58 was the most potent 
AI, which caused reduction of cell viability in an aromatase-dependent manner and 
induced a reduction on the expression of the enzyme. Even though the effect of compound 
60 was aromatase independent, it caused the most drastic decrease in MCF-7aro cell 
viability, suggesting that other biological mechanisms may be involved in the anti-tumor 
efficacy of this AI. In addition, for all the AIs the decrease in cell viability was 
accompanied by a cell cycle arrest and occurrence of apoptosis, by activation of the 
mitochondrial pathway.  
Thus, this work contributed to the elucidation of the steroid structural 
modifications in scaffold in order to design and synthesize effective AIs that inhibit tumor 
growth. In addition it contributed to the characterization of the mechanisms involved in 
the anti-tumor properties which may unravel new therapeutic targets.   
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